September 11, 2024
StemRIM Inc.

Notice Regarding Differences between Non-consolidated Results for Fiscal Year Ended July 31, 2024 and those for Previous Fiscal Year

Osaka, Japan, September 11, 2024 – StemRIM Inc. (TSE: 4599, President and CEO: Masatsune Okajima; "StemRIM") announces differences between its non-consolidated results for fiscal year ended July 31, 2024 (from August 1, 2023 to July 31, 2024) and those for previous fiscal year, as follows:

1. Difference between the Full-Year Results for the Fiscal Year Ended July 31, 2024 (August 1, 2023 to July 31, 2024) and the Previous Fiscal Year

	Operating revenue	Operating income	Ordinary income	Net income	Net Income per share
	Millions of Yen	Millions of Yen	Millions of Yen	Millions of Yen	Yen
Results for Previous Fiscal Year (A)	2,350	142	145	168	2.80
Results for Fiscal Year Ended July 31,2024 (B)	—	(2,076)	(2,077)	(2,022)	(32.98)
Difference (B-A)	(2,350)	(2,218)	(2,223)	(2,190)	
Difference (%)	—	—	—	—	

2. Reasons for the Difference

Regarding individual business results, in the fiscal year ended July 31, 2023, we recorded milestone income due to the start of thr global Phase2 clinical trial of the "Regeneration-Inducing Medicine™", Redasemtide for Ischemic Storoke, but in the fiscal year ended July 31, 2024, we did not record any milestone income or lump-sum payments, so our operating revenue decreased compared to the results of the previous fiscal year. In addition, in terms of profit and loss, all profits decreased due to the decrease in operating revenue.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. "Regeneration-Inducing Medicine™" is aimed at

maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from "Regeneration-Inducing Medicine™" include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
Twitter: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)